AATD
Oct 18, 2022
CHMP Reviews Takeda’s Qdenga; FDA Sets Date for Gilead’ Trodelvy Review; Odyssey’s Announces $ 168 Million Series B Financing; Tavros and Vividion Signs Agreement; Pharming Submits Leniolisib for Approval in the EU; FDA Fast Track Designation to Mereo’s Alvelestat
CHMP Gives Positive Opinion on Takeda’s Qdenga The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its approval to Takeda GmbH’s Qdenga, a live, attenuated dengue tetravalent vaccine (TAK-003). It is the first time the CHMP has reviewed a medicinal product ...
Read More...
Apr 12, 2021
Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market
Alpha1-antitrypsin deficiency (AATD) was first identified by Carl-Bertil Laurell and Sten Eriksson (Laurell and Eriksson 1963) in 1963, who discovered a link between low plasma serum AAT levels and pulmonary emphysema symptoms. With time as the understanding of the genetic abnormalities grew, AAT deficiency c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
